WASHINGTON — The CEO of the drug maker that sells the EpiPen allergy-reaction injector defended the corporate’s six-fold worth will increase Wednesday in congressional testimony, portray the lifesaving remedy as much less worthwhile than it’d seem.
Regardless of Mylan CEO Heather Bresch’s greatest effort to to squelch her firm’s position within the political firestorm over pharmaceutical income, she was assailed in a bipartisan refrain over the will increase. EpiPen has gone from $100 for a two-pack in 2009 to $608 at the moment.
Mylan raised EpiPen costs “to get filthy wealthy on the expense of our constituents,” Rep.Elijah Cummings, D-Md., stated on the Home Oversight Committee listening to.
Bresch, nevertheless, stood her floor when it got here to the worth, not apologizing. She stated there’s a misunderstanding concerning the profitability of the remedy, which is stocked by people and by many colleges across the nation and requires common alternative when it expires.
“I do know there’s appreciable concern and skepticism concerning the pricing,” Bresch stated. “I assume many individuals incorrectly assume we make $600 off every EpiPen. This is just not true.”
Bresch stated the corporate receives $274 per two-pack after rebates and costs are deducted. When factoring in “our price of products” and different “associated prices,” she stated the corporate reaps a revenue of $100 per two-pack.